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Abstract
Immunotherapy for Alzheimer’s disease (AD) relies on antibodies directed against toxic amyloid-beta peptide (Ab), which
circulate in the bloodstream and remove Ab from the brain [1,2]. In mouse models of AD, the administration of anti-Ab
antibodies directly into the brain, in comparison to the bloodstream, was shown to be more efficient at reducing Ab plaque
pathology [3,4]. Therefore, delivering anti-Ab antibodies to the brain of AD patients may also improve treatment efficiency.
Transcranial focused ultrasound (FUS) is known to transiently-enhance the permeability of the blood-brain barrier (BBB) [5],
allowing intravenously administered therapeutics to enter the brain [6–8]. Our goal was to establish that anti-Ab antibodies
delivered to the brain using magnetic resonance imaging-guided FUS (MRIgFUS) [9] can reduce plaque pathology. To test
this, TgCRND8 mice [10] received intravenous injections of MRI and FUS contrast agents, as well as anti-Ab antibody, BAM-
10. MRIgFUS was then applied transcranially. Within minutes, the MRI contrast agent entered the brain, and BAM-10 was
later found bound to Ab plaques in targeted cortical areas. Four days post-treatment, Ab pathology was significantly
reduced in TgCRND8 mice. In conclusion, this is the first report to demonstrate that MRIgFUS delivery of anti-Ab antibodies
provides the combined advantages of using a low dose of antibody and rapidly reducing plaque pathology.
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Introduction
Evidence of Ab toxicity, including in the brain of people with AD
[11], reinforces the need to improve current anti-Ab treatment.
Current treatments in AD patients require the long-term admin-
istrationofhigh dosesofantibodiesagainst Ab inthe bloodstreamin
order to remove Ab plaques from the brain of AD patients [12,13].
In mouse models of AD, cognitive improvement following
immunotherapy was obtained with intravenous or intraperitoneal
administration of high doses of 500 mg of anti-Ab antibodies
[14–16]. Considering that only up to 0.1% of anti-Ab antibodies
administered peripherally can reach the brain [17], most,
administered antibody remains in the bloodstream. Recently, it
was shown in transgenic mice that a low dose of anti-Ab antibodies
administered directly into the brain was more efficient at clearing
Ab than peripheral injections of high doses of antibodies, with a
concomitant reduction in vascular Ab-pathology [3]. Targeted
delivery of antibodies in the brain allows for a greater proportion of
anti-Ab antibodies to reach the affected brain region, which may
result in better treatment efficacy in AD patients.
Direct delivery of anti-Ab antibodies into the brain of animal
models by intracranial injection [18] or skull-cap removal [4] is
known to reduce plaque load within 3 days, however the invasive
nature of these procedures would raise serious safety concerns in
humans. Alternatively, transcranial MRIgFUS is a relatively non-
invasive approach of delivering therapeutics to the brain. It has
been shown to transiently enhance the permeability of the blood-
brain barrier (BBB) [5] and allow for the delivery of therapeutic
agents, as large as antibodies, into the brain of animals [6,7].
Previous studies investigating the mechanisms of MRIgFUS
delivery have reported localized transport of agents across the BBB
by transcytosis and the widening of tight junctions and channels
[19,20]. These effects on the BBB were reversible when FUS was
maintained at a pressure amplitude of 0.4 MPa or less [21].
Between 4–6 hours following treatment, the integrity of the BBB
was restored and no cellular or neuronal damage was detected.
This report assessed the delivery of anti-Ab antibodies by
MRIgFUS and the efficacy of this treatment to reduce Ab plaque
pathology. Specifically, our main objectives were to: 1) rapidly
deliver anti-Ab antibodies to the brain using MRIgFUS and a low
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10549(40 mg) intravenously-injected dose of anti-Ab antibody, and 2)
evaluate whether this treatment reduces Ab plaque load in
TgCRND8 mice within a short time-frame of 4 days.
Methods
Transgenic mice
TgCRND8 mice encode a double mutant form of amyloid
precursor protein 695 (KM670/671NL/V717F) under the control
of the PrP gene promoter [10]. TgCRND8 mice develop amyloid
pathology by 3 months of age which is accompanied by cognitive
deficits [10,22]. These mice have been well characterized in
various immunization paradigms [23,24]. Male and female
TgCRND8 mice [10] of 132–137 days in age were used in this
study, an age when only compact plaques are found in the cortex
[10].
These studies were conducted with the approval of the Animal
Care Committee of Sunnybrook Health Sciences Centre and in
compliance with the guidelines established by the Canadian
Council on Animal Care and the Animals for Research Act of
Ontario.
MRI-guided FUS delivery
Mice were anaesthetized with ketamine (150 mg/kg) and
xylazine (10 mg/kg). An angio-catheter was inserted into the tail
vein and the mouse secured in a supine position (Fig. 1B). The
FUS system was placed inside a 3.0T MRI for positioning of the
target locations using an RF coil with inner dimensions of 3.2 cm
by 4.2 cm [9]. A FUS beam was generated from a piezoelectric
transducer (10 cm diameter, 8 cm radius of curvature, 0.558 MHz
resonant frequency) positioned inside a degassed water tank using
an MRI-compatible three-axis motorized system [9]. Four spots,
1.5 mm apart, along the right hemisphere were targeted with
ultrasound (0.3 MPa, 120 s, 10 ms bursts/Hz). Definity micro-
bubbles (160ml/kg; Bristol Meyers Squibb; mean size 1–2 mm),
MRI contrast agent Gadovist (0.1 ml/kg, Schering AG, Berlin,
Germany) and 40 mg of BAM-10 antibody (A5213, Sigma Aldrich,
St Louis, MO, USA) were delivered through the tail vein at the
time ultrasound was applied. BAM-10 is directed against the N-
terminus of Ab (residues 1–10), which represents the optimal
target for Ab clearance [25]. BAM-10 has been shown to be
effective at dissociating Ab aggregates [26] and rescuing cognitive
function [4] in mouse models of AD. MRI images were captured
to determine the extent of BBB disruption based on the increase of
signal intensity from the contrast-enhancement.
Biotinylated BAM-10 immunoprecipitation analysis
BAM-10 antibody (A3981, Sigma, Aldrich, St Louis, MO, USA)
was biotinylated using sulfo-NHS-LC-biotin kit (Pierce, Rockford,
IL, USA). Mice treated with MRIgFUS-delivered biotinylated
BAM-10 (as described above), were deeply anaesthetized with
ketamine (250 mg/kg) and xylazine (17 mg/kg) for intracardial
perfusion with saline. Brains were removed and regions from the
right and left hemispheres were dissected. Tissue from each
hemisphere was homogenized and equalized to 2.5 mg/ml.
Lysates (200 ml) were incubated with 20 ml of protein A/G beads
(SC-2003, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
at 4uC overnight. Antibody was eluted using 20 mlo f2 6Laemli
sample buffer and boiled for 10 min at 95uC. Samples were run in
10% SDS-PAGE and transferred to nitrocellulose membrane.
After blocking with 5% milk in TBS-T membranes were incubated
with peroxidase conjugated streptavidin (1:2,000; Jackson Immuno
Research Laboratories, Inc., West Grove, PA, USA) and
visualized with chemiluminescence using ECL.
Co-localization time course of BAM-10 and plaques using
immunofluoroscent staining
Sections from mice treated with biotinylated BAM-10 and FUS
were incubated with a primary antibody against Ab (rabbit
polyclonal Ab42; 1:100; Millipore Corp., Temecula, CA, USA)
followed with donkey anti-rabbit Cy3 antibody to reveal Ab
(1:100; Jackson Immuno Research Laboratories, Inc., West Grove,
PA, USA) and streptavidin-Alexa 488 to reveal biotinylated BAM-
10. Fluorescent labeling was detected by confocal microscopy
(Zeiss Axiovert 100M, LSM 510; Carl Zeiss, Don Mills, Canada).
Detection of biotinylated BAM-10 and Ab plaques
Detection of the biotinylated BAM-10 antibody was revealed
with streptavadin-horseradish peroxidase (Vectastain Elite, Vector
Laboratories, Burlingame, CA, USA) followed by 3,39-diamino-
benzidine (DAB) (Sigma, St Louis, MO, USA).
For the immunostaining of plaques with the anti-Ab antibody
6F3D, sections were pre-treated with 70% formic acid, 3%
hydrogen peroxide in 100% methanol, washed and incubated
overnight at 4uC with 6F3D (1:400; Dako North American Inc.,
Carpinteria, CA, USA). Sections were then incubated with
biotinylated donkey anti-mouse IgG secondary antibody (1:100;
Jackson Immuno Research Laboratories, Inc., West Grove, PA,
USA). 6F3D-biotin complexes were revealed with streptavadin-
horseradish peroxidase (Vectastain Elite, Vector Laboratories,
Burlingame, CA, USA) and DAB. Brightfield images were
captured with Zeiss Imager M1 microscope coupled to a digital
camera, motorized stage, and the Virtual Slice module (MBF
Bioscience, Williston, VT, USA).
To ensure that BAM-10 antibody does not prevent the binding
of the antibody 6F3D to amyloid plaques, the above immunohis-
tochemistry procedures were carried out with double-staining of
streptavadin-Cy2 (1:200; Jackson Immuno Research Laboratories,
Inc., West Grove, PA, USA) to label BAM-10 antibody and
donkey anti-mouse Cy3 (1:100; Jackson Immuno Research
Laboratories, Inc., West Grove, PA, USA) to label 6F3D. The
staining for both antibodies was visualized by confocal microscopy
(Zeiss Axiovert 100M, LSM 510; Carl Zeiss, Don Mills, Canada).
Stereology
MRI post-treatment scans were used to identify the area of
BBB opening (indicated by the increase in intensity where
gadolinium entered the brain) and were measured using Matlab
software. The averaged measurements were then used to map
out equivalent contours using Stereo Investigator (5.05.1
software; MBF Bioscience, Williston, VT, USA) on the right
and left primary and secondary motor cortical regions of brain
sections stained for plaques with 6F3D, as described above.
According to a randomly selected start point (within 1.94 mm
anterior and 0.34 mm posterior of Bregma; a region normally
abundant with plaques and within the treatment area), plaque
quantification for each animal was based on 6-7 sections at an
interval of one in 9. Stereology was performed within each
contour with a Zeiss Axioplan 2 microscope coupled to a DEI-
750 CE video camera (Optroni c s ,G o l e t a ,C A ,U S A )a n da
software-driven Ludl X-Y-Z motorized stage (Ludl Electronic
products, Hawthorne, NY, USA) for estimation of plaque
number (optical fractionator) and size (nucleator probe) h~ ð
17 mm, asf ~ area of counting frame=area of sampling grid~
250 mm | 250 mm=150 mm | 150 mmÞ.
Biochemical analysis of Ab levels
Mice were perfused as described above with saline only and
brains were dissected by region. Treated and contralateral areas
MRIgFUS Ab Immunotherapy
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were homogenized in a 20 mM Tris-buffered solution contain-
ing 0.25 M sucrose, 1 mM EDTA, 1 mM EGTA, and a 1%
protease inhibitor cocktail (Calbiochem, La Jolla, CA, USA).
The homogenate was separated into two portions for total and
soluble Ab analyses as we have previously published [27].
Soluble Ab was extracted using DEA/NaCl solution, followed
by centrifugation. The supernatant was removed and neutral-
ized for soluble Ab analysis. The total fraction was solubilized in
cold formic acid, followed by sonication and centrifugation. The
supernatant was similarly collected and neutralized. Ab40 and
Ab42 levels were determined using commercially available
ELISA kits (BioSource, Invitrogen, Burlington, ON, Canada).
Ab levels were normalized using total protein concentration as
determined using Bio-Rad assays (Bio-Rad Laboratories, Mis-
sissauga, ON, Canada).
Statistical analysis
Statistical analysis was performed using SPSS 17.0 Software.
Two-tailed, paired t-tests, a=0.05, n=6 for all groups, were used
to determine significance between plaque pathology from left
versus right hemispheres of the brain for mice in all treatment
Figure 1. Magnetic resonance imaging-guided focused ultrasound (MRIgFUS) increases the permeability of the blood brain barrier
(BBB). T1-weighted contrast-enhanced MRI scans were used to position ultrasound foci prior to treatment (A) and following transcranial FUS (B–D),
were used to monitor the entry of gadolinium in the brain. Mice were positioned in a supine position (B) and injected in the tail vein with
microbubbles and gadolinium while ultrasound was applied to 4 aligned spots on the right hemisphere of the brain. Increased BBB permeability was
monitored by MRI, visualizing contrast enhancement by the influx of gadolinium (B–D). [A–D: 1286128, TE/TR=10.4/500.0, FOV=4cm, Slice 1mm,
ETL=4, 3NEX]. Scale bars: A, C, D=0.5 cm.
doi:10.1371/journal.pone.0010549.g001
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effect on Ab pathology between treatment groups.
Results
Magnetic resonance imaging-guided focused ultrasound
(MRIgFUS) locally increases the permeability of the blood
brain barrier (BBB)
For antibody delivery through the BBB, three-planar MRI scans
were used to position four ultrasound foci along the rostro-caudal
axis of the right brain hemisphere of TgCRND8 mice (Fig. 1A–
D). Mice received a tail vein administration of ultrasound
microbubbles (Definity, 160 ml/kg) to disrupt the BBB, and the
MRI contrast agent gadolinium (Gadovist, 0.1 ml/kg), at the onset
of transcranial MRIgFUS application (0.3 MPa for 120 s, pulsed
for 10 ms at 1Hz; below the reported threshold of damage [21]).
The entry of gadolinium into the right, targeted hemisphere was
observed within 5–10 min following MRIgFUS in the presence
and absence of anti-Ab antibody, BAM-10, confirming a localized
disruption of the BBB (Fig. 1B–D). When the enhancement seen
at the site of BBB disruption was #20%, in MRI post-treatment
scans acquired 10-15 minutes post-treatment, we found no red
blood cells detected in the brain parenchyma using Prussian blue
staining (not shown).
Intravenously injected BAM-10, an anti-Ab antibody,
rapidly entered the brain in areas targeted with MRIgFUS
We then evaluated whether MRIgFUS could deliver a low
peripheral dose of BAM-10 into the brain. The same experimental
settings, as described above (Fig. 1B), were used except BAM-10
was biotinylated to facilitate the downstream detection of BAM-
10. At all time points post-MRIgFUS (4 hr, 2 and 4 days),
biotinylated-BAM-10 was found bound to Ab plaques only on the
right, MRIgFUS-targeted side of the brain. Localized delivery of
biotinylated-BAM-10 to the right hemisphere was demonstrated
by immunohistochemistry (Fig. 2A), and immunoprecipitation
combined with western blotting (Fig. 2B). Co-localization of
biotinylated-BAM-10 (Fig. 2C–E9, green) with Ab plaques,
stained with rabbit anti-Ab42 antibody (Fig. 2C–E9, red), was
confirmed using confocal microscopy. On the right side of the
brain, treated with MRIgFUS, all anti-Ab42 antibody positive
cortical plaques were also immunopositive for biotinylated-BAM-
10, as illustrated in the representative fields of view in Fig. 2. In
contrast, on the untreated left hemisphere of the same brain
sections, plaques stained only for the rabbit anti-Ab42 antibody
and no biotinylated-BAM-10 was detected. Therefore, in the
current conditions, BAM-10 was delivered from the peripheral
circulation to the brain only in MRIgFUS targeted areas of the
right hemisphere.
MRIgFUS delivery of BAM-10 to the brain reduces Ab
plaque pathology
The therapeutic effects of BAM-10 delivery to the brain were
evaluated by assessing plaque pathology in cortical areas targeted
by MRIgFUS (right hemisphere, presence of BAM-10) to those
not targeted by MRIgFUS (left hemisphere, absence of BAM-10).
Four month-old TgCRND8 mice were randomly assigned to 4
treatment groups: BAM-10/FUS (treated with MRIgFUS and a
single 40 mg, i.v. dose of BAM-10), FUS (treated with MRIgFUS
but no BAM-10), BAM-10 (40 mg BAM-10 i.v., no MRIgFUS),
or untreated (no MRIgFUS, no BAM-10). All groups received
the same anesthetic procedures. With the exception of the
untreated group, all groups were injected with microbubbles and
gadolinium in the tail vein. MRIgFUS was applied only to the
right hemisphere (as in Fig. 1). Four days later, brains were
collected and processed for staining with the anti-Ab antibody
6F3D. To ensure that the delivered BAM-10 antibody did not
prevent the binding of 6F3D to Ab plaques, sections from mice
that had been treated with MRIgFUS-delivered biotinylated
BAM-10 were stained for plaques with 6F3D (red, Fig. 3A) and
for detection of BAM-10 antibody with strepavidn-Cy2 (green,
Fig. 3B). 6F3D was clearly detected on all BAM-10-positive
plaques (Fig. 3C).
Plaques stained for 6F3D (Fig. 3D,E) were quantified in 6–7
sections per animal, using design-based stereology for all groups of
mice. Quantification of plaque load was based on Ab plaque
numbers (optical fractionator), cross-sectional area (nucleator) and
surface area of Ab (plaque number X mean cross-sectional area).
Among all groups (untreated, FUS-, BAM-10-, BAM-10/FUS-
treated; n=6 for all groups), statistically significant differences in
plaque pathology were found only in BAM-10/FUS-treated mice,
comparing the left (untreated) and right (treated) sides of the brain
for each mouse (paired t-tests, Fig. 3F,G,H). In all mice treated
with BAM-10/FUS there were fewer plaques on the right,
MRIgFUS-targeted hemisphere (12% reduction), in comparison
to their respective contralateral sides (p=0.008, n=6, paired t-
test, Fig. 3F). The mean plaque size was lower on the right
hemisphere, in comparison to the left, in 5 out of 6 BAM-10/FUS-
treated mice, representing a significant reduction in plaque size
(12% mean reduction, Fig. 3G). Further, the estimated surface
area covered by Ab plaques was significantly smaller on the right
compared to the left hemisphere (p=0.003, n=6, paired t-test,
Fig. 3H) for all mice in the BAM-10/FUS group, with a mean
reduction of 23%. Other groups (Fig. 3F9–H9,3 F 0–G0), including
FUS alone (not shown), had no significant difference in the
number of plaques, mean plaque size and surface area covered by
Ab plaques between hemispheres (p.0.05).
MRIgFUS-delivery of BAM-10 and Ab levels after 4 days
Once established that MRIgFUS-delivered BAM-10 could
reduce plaque burden after a single treatment, we used Ab
ELISAs to determine Ab40 and Ab42 levels in untreated, BAM-
10/FUS-, BAM-10-, and FUS-treated mice. Among all groups,
there was no significant difference due to treatment (ANOVA,
p.0.05). Paired t-tests indicated no statistically significant left-to-
right differences in the levels of Ab40 (total, Fig. 4A; soluble,
Fig. 4B) and Ab42 (total, Fig. 4C; soluble Fig. 4D) in any of the
groups (shown are untreated and BAM-10/FUS).
Discussion
We demonstrated that MRIgFUS efficiently delivered the anti-
Ab antibody, BAM-10, from the bloodstream to the brain. Once
in the brain, BAM-10 bound to Ab-plaques within hours and
remained associated with plaques for at least 4 days. Importantly,
we report for the first time that a single MRIgFUS treatment in
conjunction with one low dose (40 mg) of intravenous BAM-10
anti-Ab antibodies reduces the pathology of compact plaques in
TgCRND8 mice in terms of the number, mean size and surface
area occupied by Ab. We found no significant difference in total
and soluble Ab loads measured by ELISA. Similar findings have
been previously demonstrated in TgCRND8 mice after prolonged
active immunization with Ab42 [23]. Similarly, Dodart and
colleagues reported changes in plaque levels without changes in
Ab levels in PDAPP mice [28].
At 4 days post-treatment, right cortical areas that received
BAM-10 by MRIgFUS delivery had reduced plaque pathology
MRIgFUS Ab Immunotherapy
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plaque burden was evident based on the number or size of plaques
alone (12% reduction in both cases), and the total surface area of
Ab plaques (23% reduction). Considering the variability in the
number of plaques in TgCRND8 mice at this age, no significant
difference in plaque load was observed between treatment groups.
TgCRND8 mice exhibit a very rapid accumulation of Ab at 4
months of age, resulting in large variances in plaque numbers in all
groups of TgCRND8 mice. To evaluate the impact of a single
MRIgFUS treatment with BAM-10 on plaque load within each
animal, we focused our analyses on pair-wise comparisons of right
(treated) and left (untreated) sides of the brain.
The reduction of plaque load in TgCRND8 mice, on the
BAM-10/FUS treated hemisphere compared to the untreated
side of the brain, was achieved rapidly – within 4 days – and with
a single low dose of 40 mgo fa n t i - A b antibody. Previous passive
immunization studies in AD mouse models, where plaque
pathology was reduced [4,14–16,28], required the systemic
administration of anti-Ab antibodies at concentrations that were
10-fold higher and repeated weekly over several months. Here,
the delivery of anti-Ab antibodies to the brain using non-surgical
MRIgFUS yielded a significant reduction in Ab plaque
pathology 4 days after a single treatment. This timeframe of
treatment efficacy is comparable to the administration of
antibodies directly into the brain using invasive intracranial
delivery [4,18]. Interestingly, in our experimental conditions, we
observed that MRIgFUS delivered antibodies to widespread
areas of the cortex, thereby targeting all plaques, as illustrated by
the co-localization of biotinylated-BAM-10 with Ab-positive
plaques (Fig 2C9–E9).
Figure 2. BAM-10 entered the right, MRIgFUS-treated, side of the brain and bound to Ab plaques. Following intravenous (i.v.)
administration of biotinylated BAM-10 and treatment with MRIgFUS, the entry of biotinylated BAM-10 into the brain of TgCRND8 mice was evaluated
by processing brain sections with streptavidin-horseradish peroxidase and standard histochemistry procedures (A). Biotinylated BAM-10 was not
found on left side of the brain (A9). In contrast, the right side of the brain, exposed to FUS, had abundant biotinylated BAM-10-deposits (A0).
Biochemical analysis of brain tissue by immunoprecipitation and western blotting (B, 4 mice represented) also showed that biotinylated BAM-10 was
not detected on the left (B, L) and abundant on the right (B, R) side of the brain, which received MRIgFUS. Brain sections from mice sacrificed at
4 hours (C, C9), 2 days (D, D9) and 4 days (E, E9) post-treatment were double stained with streptavidin-Alexa 488 to detect biotinylated BAM-10
(green) and a rabbit Ab42 antibody conjugated with Cy3 (red). Biotinylated BAM-10 was present at all time points on the right side of the brain
receiving MRIgFUS and it co-localized with Ab-positive plaques. Scale bars: A=1 mm; A9,A 0=100 mm; C-E9=50mm.
doi:10.1371/journal.pone.0010549.g002
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PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10549Using a different mouse model of AD (B6C3-Tg), Raymond
et al. suggested that anti-Ab antibodies given intravenously could
enter FUS-targeted areas of the brain [8]. We are the first to show
that the delivery of anti-Ab antibodies to the brain using
MRIgFUS has a significant therapeutic effect. This represents a
substantial advance to the field of MRIgFUS anti-Ab antibody
delivery. We used MRIgFUS, in contrast to FUS alone, to adjust
the location of treatment foci and monitor changes in the
permeability of the BBB during the experiment. We achieved
significant BAM-10 delivery in MRIgFUS targeted brain areas
with one BAM-10 dose of 40 mg (i.v.), which is 100 times lower
than the dose of anti-Ab antibody previously used for FUS-
delivery to the brain [8]. We have also established the clear co-
localization of BAM-10, delivered by MRIgFUS to the brain, with
existing Ab-positive plaques identified with another Ab-specific
antibody. Lastly, we demonstrated MRIgFUS immunotherapy
can quickly decrease compact plaque burden after a single
treatment in a model of AD with aggressive Ab pathology.
In conclusion, this is the first report to demonstrate that
MRIgFUS delivery of anti-Ab antibodies rapidly reduces plaque
pathology. Immunotherapy treatments showing efficacy within a
short time-frame could offer significant clinical benefits to people
Figure 3. Focused ultrasound delivery of BAM-10 to the brain reduces Ab plaque pathology in TgCRND8 mice. Coronal sections were
stained with streptavadin-Cy2 for (A) biotinylated BAM-10 and (B) anti-Ab antibody 6F3D for plaques to demonstrate that 6F3D binds to plaques
which are strongly (arrows) and weakly (arrowheads) positive for BAM-10 (C). Once it was confirmed that BAM-10 does not interfere with 6F3D
plaque detection, sections for mice in each treatment group were stained with 6F3D and the stereology software was used to draw contours
outlining the FUS-targeted region (determined from MRI post-treatment scans) on the right side of the brain and an equivalent region on the
contralateral side (D). Plaques were counted and measured at high magnification (E), using stereological methods. In 4 days, the mean (F) count, (G)
size and (H) surface area of Ab plaques on the right, MRIgFUS-targeted side of the brain was consistently reduced in comparison to the left side of the
brain only for the BAM-10/FUS-treated mice (F–H; n=6, paired t-tests, p=0.008, p=0.048 and p=0.003, respectively). This difference is unique to
BAM-10/FUS treatment as there was no significant difference between right and left side of the brain in mice from other treatment groups (F9–H9:
BAM-10 treated group, n=6, paired t-tests, p=0.294, p=0.941 and p=0.402; F0–H0: Untreated group, n=6, paired t-tests, p=0.502, p=0.690,
p=0.610). Scale bars: A–C=100 mm (inset=20 mm); D=1 mm; E=50 mm.
doi:10.1371/journal.pone.0010549.g003
Figure 4. Ab levels in TgCRND8 mice after one BAM-10/FUS treatment. Cortical homogenates were analyzed for total Ab40 (A), soluble Ab40
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high-field micro-MRI shows promise for detecting Ab plaques in
vivo [29]. Eventually, the combination of MRI and FUS could
provide the benefit of using micro-MRI to image plaques in vivo,
and target these areas with FUS-delivered anti-Ab antibodies. This
imaging and delivery system could potentially offer the opportu-
nity for a more tailored therapy and the ability to monitor the
efficacy of treatment in vivo.
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